Parnell announced the launch of Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution, a Class III controlled veterinary product formulated for humane, painless, and rapid euthanasia of dogs, available in 100 mL multi‑dose vials.
Designed for clinical reliability and ease of identification in practice settings, Parnell’s formulation contains 390 mg/mL pentobarbital sodium and 50 mg/mL phenytoin sodium, with Rhodamine B (bluish‑red dye) to clearly distinguish it from parenteral drugs intended for therapeutic use.
“At Parnell, we understand the responsibility veterinarians carry during end‑of‑life care,” said Pablo Lamberto, DVM, SVP and President of U.S. Operations for Parnell. “We are proud to offer a solution that supports compassionate, calm, and dignified experiences for dogs and the people who care for them.”
Parnell’s Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution is now available to U.S. veterinary practices via distributor partners. For more information, visit www.parnell.com or contact your local distributor representative.
About Parnell
Parnell is a veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. We currently manufacture and market products for companion and production animals in 10 countries.
For more information please visit, www.parnell.com.